Omega-3 fatty acids improve quality of life, outcomes in cancer
the ONA take:
According to a new study published online ahead of print in the Journal of Parenteral and Enteral Nutrition (JPEN), researchers at the University Hospitals of Leicester in the United Kingdom have found that the addition of omega-3 fatty acids to anti-cancer medications may improve quality of life and treatment outcomes in patients with cancer.
For the study, researchers enrolled 150 patients with advanced pancreatic cancer. Participants received gemcitabine 1,000 mg weekly followed by up to 100 g of omega-3 rich lipid emulsion for 3 weeks followed by 1 rest week. Patients received up to six cycles until disease progression, unacceptable toxicity, patient request, or death.
Results showed that patients who received omega-3 fatty acids experienced an improvement in response activity and disease stabilization rates, a reduction in liver metastases volume, and improved quality of life.
The findings suggest that further investigation is warranted to evaluate the addition of omega-3 fatty acids with a chemotherapy agent in a randomized phase III trial.
Addition of omega-3 fatty acids to anti-cancer medications may improve quality of life and treatment outcomes in patients with cancer.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|